High Conviction Growth – ADD to GQG Partners
Add to GQG Partners
Balanced Portfolio
High Conviction – Add Telix Pharmaceuticals
As of August 5, 2025 (mid-morning AEST), Telix Pharmaceuticals (TLX) is trading around A$16.84–16.75, down approximately 17% from its previous close of A$20.24. This sharp intraday decline aligns closely with your noted price of $17 (assuming AUD). Below, I’ll address the reasons for this correction based on recent developments and why it still represents a strong buying opportunity to add to positions.
High Conviction – Switch WIRE ETF to Silver ETF
SELL WIRE ETF
to ADD to Silver ETF
High Conviction – TRIM CSL to BUY Sigma Healthcare SIG:ASX
TRIM CSL to BUY Sigma Healthcare SIG:ASXADD to GQG Partners GQG:ASX
High Conviction Growth – ADD Telix Pharma TLX:ASX
Shares have dropped on a routine SEC enquiry after the company disclosed earlier this morning that they were on track for guidance
High Conviction Growth – BUY Tetratherix TTX:ASX
Tetratherix is an Australian biotech company with a simple but powerful mission: help the body heal itself. The company has developed an advanced gel technology called Tetramatrix which has been called Medical Lego
High Conviction Global: TSLA & ISRG Earnings this week
TSLA & ISRG Earnings this week, both near buy range
High Conviction – ADD to GQG Partners GQG:ASX
High Conviction – Growth at a reasonable Yield
ADD to GQG Partners GQG:ASX
High Conviction Small Caps – SELL Johns Lyng Group JLG:ASX Takeover bid
SELL Johns Lyng Group (ASX: JLG) Company News – Takeover offer
Thematic ETF: BUY Defense Tech ETF DTEC:ASX
The Global X Defense Tech ETF (DTEC) is strategically positioned to benefit from a significant and sustained increase in global defense spending.
High Conviction Mining: BUY Northern Star NST:ASX
BUY the remaining 50% <$17.20 (20% saving) On the 17th of June @ $21. Due to poor price action we only Bought 50% of intended allocation
High Conviction Growth: Xero XRO:ASX Update
Xero has announced it has entered into a binding agreement to acquire 100 per cent of US company Melio, with $3.9 billion in cash and scrip in upfront consideration.